IP Portfolio
| USP 6,666,886 | Tissue equivalent approach to a tissue-engineered cardiovascular valve |
| USP 8,192,348 | Engineered blood vessels |
| USP 10,111,740 | Decellularized biologically-engineered tubular grafts |
| USP 10,105,208 | Decellularized biologically-engineered tubular grafts |
| USP 10,893,928 | Decellularized biologically engineered tubular grafts and valves |
| PCT/US2017/026204 | Decellularized biologically engineered tubular grafts and valves |
| PCT/US2018/026502 | Tri-tube heart valve for strong commissures |
| PCT/US17/64559 | Venous valves |
| PCT/US18/40510 | Tissue grafts |
| US 62/645,698 & 62/652,848 | Alternative stent tri-cuspid |
| US 62/674,487 | Sutureless valve |
| US 62/507,758 | Covered stent |
| US 62/674,494 & 62/674,513 | Engineered tissue valves |
| US 62/684,147 | Orthotopic or inverted tricuspid |
News
Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury
Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference
Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility
Vascudyne’s TRUE Tissue Technology is a Top 3 2022 Better World Project Award Finalist
Regenerative Medicine Company Vascudyne Closes $10 Million Series A Financing
Vascudyne announces successful First Human Use of TRUE™ Vascular Graft for hemodialysis access
Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb
Lab-created heart valves can grow with the recipient article published in Science Translational Medicine
Proud Member of:
Copyright 2021 | Vascudyne, Inc.
